SELLAS Life Sciences Receives $28.7M from Warrant Exercises, Boosting Cash Position
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS Life Sciences Group announced it received $28.7 million from warrant exercises, further strengthening its cash position and increasing its outstanding share count.
Key Events · Financing and Capital Events · SLS
-
$28.7 Million Cash Inflow
The company received approximately $28.7 million in proceeds from the exercise of common stock warrants during April and May 2026.
-
Updated Cash Position
This adds to the $107.1 million cash and cash equivalents reported as of March 31, 2026, further bolstering the company's financial runway.
-
Increased Share Count
As of June 2, 2026, the total common stock outstanding increased to 196,632,574 shares due to these warrant exercises.
Analysis · SLS · Life Sciences
This 8-K details a significant cash inflow of $28.7 million from common stock warrant exercises in April and May 2026. This strengthens the company's balance sheet, adding to the previously reported robust cash position, and provides additional capital for ongoing operations and clinical trials. The exercises also indicate investor confidence, especially as the stock trades near its 52-week high and follows recent positive clinical trial updates.
At the time of this filing, SLS was trading at $9.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $1.39 to $9.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.